Abstract library

2183 results for "Multiple Endocrine Neoplasia".
#58 Surgical approaches in 84 patients with insulinomas in multiple endocrine neoplasia type 1 (MEN 1)
Introduction: Management of insulinomas in the setting of Multiple Endocrine Neoplasia type 1 (MEN1) remains controversial.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Delphine Vezzosi
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
#202 Extreme Obesity Due to Insulinoma Within Multiple Endocrine Neoplasia (MEN) 1 Syndrome
Introduction: Peak incidence of symptoms in women with multiple endocrine neoplasia (MEN) 1 is during the third decade of life. Insulinomas are present in 20% of patients and cause weight gain in 30% of patients.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ivan Kruljac
Authors: Kruljac I, Vrkljan M, ...
#1027 Chromogranin A (CgA) in Pheochromocytoma and in Multiple Endocrine Neoplasia Type 1.
Introduction: Chromogranin A (CgA) as a main, nonspecific marker of neuroendocrine tumors (NET) has been applied for diagnostic purposes and for monitoring the treatment of NET. Pheochromocytoma and MEN-1 syndrome represent rare neuroendocrine tumours.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: M.Sc., Ph.D. Piotr Glinicki
#1191 Efficacy of Lanreotide versus Follow-up in Early-stage Duodeno-Pancreatic Neuroendocrine Tumors (NETs) Related to Multiple Endocrine Neoplasia Type 1 (MEN1): Preliminary Data
Introduction: Surgery is the only curative approach for NETs, representing the first-line therapy. As most pts with MEN1 have multiple duodeno-pancreatic NETs, cure is generally not possible, unless to adopt radical surgery. Somatostatin analogues (SSAs) represent one of the main therapeutic option in functioning well-differentiated NETs. There are no perspective studies focusing on MEN1-related NETs.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: DR. Valeria Ramundo
#2000 A Case of Multiple Endocrine Neoplasia Type 2B(MEN2B)
Introduction: Familial neuroendocrine neoplasms (NENs) accounts for less than 5% of NENs and multiple endocrine neoplasia type 2B (MEN2B) is a kind of rare familial NENs.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Chen M, Chen J, ...
#2076 Pancreatic Neuroendocrine Tumor in Polish Population with MEN 1 Syndrome
Introduction: The multiple endocrine neoplasia type 1 (MEN 1) is a genetically conditioned syndrome which is characterised by usually mild parathyroid and pituary gland adenomas, pancreatic neuroendocrine tumor (pNET). The last appear in 30-70% of MEN 1 patients being main life-threatening manifstation among MEN 1 patients. The prognosis might improve by presymptomatic tumor detection.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: MD Przemysław Soczomski
#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort
Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: MD, MSc Dirk-Jan van Beek
#2732 Prostate Metastasis of Medullary Thyroid Carcinoma in a Young Patient with MEN2B Syndrome
Introduction: Multiple Endocrine Neoplasia 2B is associated with particularly early onset medullary thyroid carcinoma (MTC). Metastatic MTC is the leading cause of early death in MEN2B. The usual sites of metastasis are neck, mediastinum, lung, liver, bone and brain.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Jane Noble
Authors: Noble J, Forde H, Crowley R, ...
#349 Gastrointestinal Stromal Tumor (GIST) Of The Esophagus In A Patient With MEN-1 And-Related Pancreatic Gastrinoma
Introduction: Both Multiple Endocrine Neoplasia type 1 (MEN-1; OMIM #613733)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs; OMIM #606764) are rare neoplasms and their association has been rarely reported so far.
Conference:
Category: Basic
Presenting Author: Dr Roberta E Rossi